Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

Haematologica

Volumn 89, Issue 10, 2004, Pages 1187-1193

  Borgna Pignatti, Caterina ^a   Rugolotto, Simone ^b   De Stefano, Piero ^c   Zhao, Huaqing ^g   Cappellini, Maria Domenica ^f   Del Vecchio, Giovanni Carlo ^b   Romeo, Maria Antonietta ^b   Forni, Gian Luca ^e   Gamberini, Maria Rita ^d   Ghilardi, Roberta ^f   Piga, Antonio ^b   Cnaan, Avital ^g  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS San Matteo ^*

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Causes of death; Ferritin; Hemosiderosis; Survival; Thalassemia

Indexed keywords

DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BIRTH; BLOOD TRANSFUSION; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GENDER; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; SURVIVAL; THALASSEMIA MAJOR; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ARRHYTHMIA; BLOOD TRANSFUSION; CHELATION THERAPY; COHORT STUDIES; DEFEROXAMINE; DIABETES MELLITUS, TYPE 1; FEMALE; FERRITINS; HEART FAILURE, CONGESTIVE; HIV INFECTIONS; HUMANS; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATING AGENTS; ITALY; LIFE TABLES; MALE; RETROSPECTIVE STUDIES; SPLENECTOMY; SURVIVAL ANALYSIS; THALASSEMIA; THROMBOSIS;

EID: 20844460608     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bianco I. Clinical and therapeutic aspects of Mediterranean anaemia. Il Progr Med 1986; 42:471-5.
2. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with β-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-5.
3. Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P, et al. Marrow transplantation for thalassaemia. Lancet 1982;2:227-9.
4. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, et al. Related umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 2003;101:2137-43.
5. Zurlo MG, De Stefano P, Borgna-Pignatti A, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850:227.
7. Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyroidism. Br Med J 1973;1:657-62
8. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley. 1980.
9. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187-220.
10. StataCorp. Stata Statistical Software: Release 7.0 College Station, TX, USA. Stata Corporation.
11. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J 1982; 284:1081-4.
12. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331: 567-73.
13. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051-2.
14. Piga A, Longo F, Consolati A, DeLeo A, Carmellino L Mortality and morbidity in thalassemia with conventional treatment. Third international conference on bone marrow transplantation in thalassemia. Bone Marrow Transplant 19 Suppl 2 1997:11-3.
15. de Montalembert M, Costagliola DG, Lefrere JJ, Cornu G, Lombardo T, Cosentino S, et al. Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type 1, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. The French Study Group on Thalassaemia. Transfusion 1992;32:509-12.
16. Borgna-Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, et al. Thromboembolic events in β thalassemia major: an Italian multicenter study. Acta Haematol 1998;99:76-9.
17. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
18. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990;323: 713-9.
19. Sabato A, De Sanctis V, Atti G, Capra L, Bagni B, Vullo C. Primary hypothyroidism and the lowT3 syndrome in thalassaemia major. Arch. Dis Child 1983;58:120-7.
20. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988;63:58-62.
21. Prati D, Zanella A, Farma E, De Mattel C, Bosoni P, Zappa M, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous β-thalassemia. Blood 1998;92:3460.
22. de Montalembert M, Girot R, Mattlinger B, Lefrere JJ. Transfusion-dependent thalassemia: viral complications (epidemiology and follow-up). Semin Hematol 1995;32: 280-7.
23. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993:42:81-5.
24. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
25. Cohen A, Cohen IJ, Schwartz E. Scurvy and altered iron stores in thalassemia major. N Engl J Med 1981;304:158.
26. De Virgiliis S, Cornacchia G, Sanna G, Argiolu F, Galanello R, Fiorelli G, et al. Chronic liver disease in transfusion-dependent thalassemia: liver iron quantitation and distribution. Acta Haematol 1981;65:32-9.
27. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331:574-8.
28. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-44.
29. Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD. Healthy life expectancy in 191 countries, 1999. Lancet 2001;357:1685-91.
30. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. BrJ Haematol 2004;125:545-51.